426c.mod.core-c4b
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 22, 2022 (NCT05471076)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06613789 | Phase 1 | Feb 3, 2025 | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington |
| NCT06006546 | Phase 1 | Oct 30, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05471076 | Phase 1 | Aug 22, 2022 | Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of California, San Francisco, University of Washington |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 2 | 1 | 2022 |
| University of Washington | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2022 |
| HIV Vaccine Trials Network | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1